Harmony Biosciences (HRMY) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 50.4% versus a loss of 12.2%. Over five years, SUPN leads with a +33.1% price change compared with +2.2% for HRMY. Supernus Pharmaceuticals is the larger company by market cap ($2.48 billion vs $2.35 billion), about 1.1 times the size, while Harmony Biosciences is growing revenue faster (+21.5% vs +8.6%).
On valuation, Harmony Biosciences trades at a lower forward P/E (5.8x vs 9.6x for Supernus Pharmaceuticals). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | SUPN |
|---|---|---|
| Share price | $40.28 | $42.67 |
| Market cap | $2.35B | $2.48B |
| 1-day change | +1.72% | +1.26% |
| YTD return | +7.64% | -15.21% |
| 1-year return | +50.41% | -12.21% |
| 5-year return | +2.23% | +33.10% |
| P/E ratio (TTM) | 12.99 | — |
| Forward P/E | 5.75 | 9.57 |
| EPS (TTM) | $3.10 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $718.95M |
| Revenue growth (YoY) | +21.51% | +8.63% |
| Net income (latest FY) | $158.69M | $-38.55M |
| Gross margin | 77.16% | 89.63% |
| Operating margin | 24.00% | -8.66% |
| Net margin | 18.27% | -5.36% |
| 52-week high | $43.49 | $59.68 |
| 52-week low | $25.52 | $40.51 |
| Distance from 52-week high | -7.38% | -28.50% |
| Analyst consensus | buy | none |
| Avg. price target upside | +18.27% | +44.72% |
| Average volume | 892.55K | 756.95K |
| Shares outstanding | 58.24M | 58.22M |
| Employees | 293 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed SUPN by 62.6 percentage points over the past year.
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -5.4 cents for Supernus Pharmaceuticals.
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs +8.63%).
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
HRMY vs SUPN FAQ
Which is bigger, Harmony Biosciences or Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) is larger, with a market capitalization of $2.48B compared with $2.35B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, HRMY or SUPN?
HRMY returned +50.41% over the past 12 months, compared with -12.21% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.